Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022

Date: August 20, 2012
Pages: 173
Price:
US$ 2,635.00
License [?]:
Publisher: Visiongain
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P84136DE5C0EN
Leaflet:

Download PDF Leaflet

Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022
How does the future look for pharmaceutical contract manufacturing? Visiongain's report gives you sales predictions to 2022. You find data, trends, opportunities and commercial prospects.

That new study lets you assess forecasted revenues at overall world market, submarket, and national market level. You see how and why the contract manufacturing industry and market will grow, as we predict.

In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, including discussions of regulatory and commercial developments.

You receive 64 tables, 54 charts and two research interviews. The following sections highlight what you discover in the report.

PROSPECTS FOR SUBMARKETS

In addition to analyses of the overall world market, you see revenue forecasting of six world-level submarkets to 2022:
  • Active pharmaceutical ingredient (API) manufacturing services
  • Generic API manufacturing services
  • Highly potent API (HPAPI) manufacturing services
  • Finished dosage form manufacturing services
  • Solid dosage manufacturing services
  • Injectable dosage manufacturing services.
The work also breaks the overall world market into leading national markets.

PROSPECTS FOR LEADING COUNTRIES

Developments worldwide will influence the market, especially fast-rising demand in emerging countries. Individual national markets offer differing opportunities for contract manufacturers and companies seeking to outsource work.

In our study you discover revenue forecasts to 2022 for one regional block and 12 national markets:
  • EU
  • US
  • Japan
  • Germany, France, UK, Italy and Spain (EU5)
  • Brazil, Russia, India and China (BRIC nations)
  • South Korea.
This decade, demand for manufacturing services will rise in all leading countries. Contract manufacturing organisations (CMOs) in India and China will experience rising demand for API and generic drug manufacturing.

Also, uptake of specialist manufacturing services will benefit national markets from 2012.

REVENUE GROWTH OPPORTUNITIES FOR PHARMA CONTRACT MANUFACTURERS

Where will CMOs find the best growth opportunities from 2012? Our report shows you developmental trends and possibilities:
  • Through expansion and consolidation, contract manufacturers will be more able to form strategic partnerships with pharmaceutical companies, offering a "one-stop-shop" for drug development and manufacture.
  • Entering new geographical markets will provide the advantage of proximity for CMOs, as well as allowing them to use regional expertise.
  • Manufacturing drugs for clinical trials will allow CMOs with low capacity to compete in the market.
Discover how progress and pharmaceutical industry demands can change the sector. Our investigation explains, discussing issues.

PROMINENT ISSUES AFFECTING THE CONTRACT MANUFACTURING INDUSTRY

Our study lets you assess trends and outlooks for market growth from 2012. As the report shows, many issues will affect contract manufacturers:
  • Development of biologics for treating cancer and autoimmune diseases
  • Potential for biosimilars in the US, the EU and Japan
  • Increasing generic drug sales in developed markets as payers limit healthcare spending
  • Rising generic drug sales in emerging markets from wider access to healthcare
  • Targeted therapies and orphan indications giving opportunities and challenges.
You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry.

DISCUSSIONS OF LEADING COMPANIES AND PROSPECTS FOR MARKET GROWTH

What will happen next? Demand for outsourced manufacturing will increase from drug developers of all sizes. Revenue growth for contract manufacturers will be strong from 2012 to 2022.

Overall world revenue for that market area will reach $47.6bn in 2012, our report forecasts. Rising incidence of diseases such as cancer, arthritis and diabetes will increase demand for complex drugs and biologics.

Our study discusses 20 leading CMOs, including Catalent, Lonza and Patheon. You discover recent developments and assess outlooks for the future. Also, you see our interviews with two third party manufacturers.

Supplying HPAPIs and providing complex manufacturing services improve prospects for market growth from this decade onwards.

SEVEN WAYS PHARMACEUTICAL CONTRACT MANUFACTURING: WORLD MARKET OUTLOOK 2012-2022 BENEFITS YOU

In particular, then, our study gives you the following knowledge on pharmaceutical contract manufacturing:
  • Forecasted revenues to 2022 for the overall world market and submarkets
  • Market forecasting to 2022 for the US, Japan, the 5 leading EU countries, the BRIC group and South Korea
  • Assessment of 20 leading companies - services, activities, recent performances and outlooks
  • Review of the regulatory landscape for pharmaceutical manufacturing in leading countries
  • Opinions on the sector, including our research interviews with industry participants
  • Investigation of competition and opportunities influencing growth
  • Discussion of external and internal trends affecting industry performance.
1. EXECUTIVE SUMMARY

1.1 Pharmaceutical Contract Manufacturing: World Market Review
1.2 Report Contents
1.3 Research and Analysis Methods

2. PHARMACEUTICAL CONTRACT MANUFACTURING: AN INTRODUCTION

2.1 Outsourcing in the Pharmaceutical Industry
  2.1.1 Reasons to Outsource
  2.1.2 Benefits to Outsourcing
  2.1.3 Challenges in Outsourcing
  2.1.4 Strategic Outsourcing vs. Tactical Outsourcing
  2.1.5 Virtual Companies
2.2 Contract Manufacturing Organisations (CMOs)
  2.2.1 Manufacturing Services Offered
  2.2.2 Biopharmaceutical Manufacturing

3. THE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET 2012-2022

3.1 The Pharmaceutical Contract Manufacturing Market in 2011
  3.1.1 The Roles of Biologics and Small Molecule Drugs in the Market 2011
3.2 The Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast 2012-2022
  3.2.1 Market Drivers 2012-2022
  3.2.2 Market Restraints 2012-2022
3.3 The API Contract Manufacturing Submarket 2012-2022
  3.3.1 The API Contract Manufacturing Submarket: Revenue Forecast 2012-2022
  3.3.2 The Generic API Contract Manufacturing Submarket: Revenue Forecast 2012-2022
  3.3.3 The HPAPI Contract Manufacturing Submarket: Revenue Forecast 2012-2022
    3.3.3.1 Focus on Oncology
3.4 The Finished Dosage Form Submarket 2012-2022
  3.4.1 The Finished Dosage Form Contract Manufacturing Submarket: Revenue Forecast 2012-2022
  3.4.2 The Solid Dosage Form Contract Manufacturing Submarket: Revenue Forecast 2012-2022
  3.4.3 The Injectable Dosage Form Contract Manufacturing Submarket: Revenue Forecast 2012-2022

4. LEADING NATIONAL MARKETS FOR PHARMACEUTICAL CONTRACT MANUFACTURING 2012-2022

4.1 Supply and Demand for Contract Manufacturing Services
4.2 The Pharmaceutical Contract Manufacturing Market: Regional Breakdown 2011
4.3 The Pharmaceutical Contract Manufacturing Market: Regional Forecast 2012-2022
4.4 The US
  4.4.1 The US: CMO Revenues 2012-2022
4.5 The EU
  4.5.1 The EU: CMO Revenues 2012-2022
  4.5.2 Germany: CMO Revenues 20120-2022
  4.5.3 France: CMO Revenues 2012-2022
  4.5.4 Italy: CMO Revenues 2012-2022
  4.5.5 Spain: CMO Revenues 2012-2022
  4.5.6 The UK: CMO Revenues 2012-2022
4.6 Japan
  4.6.1 Japan: CMO Revenues 2012-2022
4.7 Pharmaceutical Contract Manufacturing in Emerging Markets
  4.7.1 Outsourcing to Emerging Markets
    4.7.1.1 Outsourcing to India and China
  4.7.2 Brazil: CMO Revenues 2012-2022
  4.7.3 Russia: CMO Revenues 2012-2022
  4.7.4 India: CMO Revenues 2012-2022
  4.7.5 China: CMO Revenues 2012-2022
4.8 South Korea
  4.8.1 South Korea: CMO Revenues 2012-2022

5. LEADING PHARMACEUTICAL CONTRACT MANUFACTURERS 2012

5.1 The Pharmaceutical Contract Manufacturing Market by Company in 2011
  5.1.1 Significant Deals in 2011 and 2012
5.2 Catalent
  5.2.1 Recent Financial Performance
  5.2.2 Strong Growth for Oral Delivery Technologies
  5.2.3 Catalent Adjusts its Services
  5.2.4 Outlook
5.3 Lonza
  5.3.1 Recent Financial Performance
  5.3.2 Lonza and Biologics
  5.3.3 Lonza and Regenerative Medicine
  5.3.4 Lonza Expands in Asia and Africa
  5.3.5 Outlook
5.4 Boehringer Ingelheim
  5.4.1 Recent Financial Performance
  5.4.2 Ben Venue Laboratories
  5.4.3 Manufacturing Deals 2011-2012
  5.4.4 Outlook
5.5 Royal DSM
  5.5.1 Recent Financial Performance
  5.5.2 DSM Reorganises its Anti-Infectives Division
  5.5.3 New Service Offerings
  5.5.4 Outlook
5.6 Patheon
  5.6.1 Recent Financial Performance
  5.6.2 Developed Market Reorganisation
  5.6.3 New Services and Focus
  5.6.4 Outlook
5.7 Dr. Reddy's Laboratories
  5.7.1 Recent Financial Performance
  5.7.2 Continued Investment in the UK
  5.7.3 Outlook
5.8 Abbott Laboratories
  5.8.1 Abbott Laboratories to Split
  5.8.2 Outlook
5.9 Jubilant Life Sciences
  5.9.1 Recent Financial Performance
  5.9.2 Manufacturing Partnerships 2011-2012
  5.9.3 Outlook
5.10 Haupt Pharma
  5.10.1 Focus on the EU, the US and Japan
  5.10.2 Outlook
5.11 Recipharm
  5.11.1 Recent Financial Performance
  5.11.2 Strategic Acquisitions 2010-2012
  5.11.3 Outlook
5.12 Pfizer
  5.12.1 Meeting Market Demands
5.13 Piramal Healthcare
  5.13.1 Recent Financial Performance
  5.13.2 US and EU Expansion
  5.13.3 Outlook
5.14 Evonik Degussa
  5.14.1 Growing Through Acquisitions
  5.14.2 Specialising in HPAPIs
5.15 Aenova
  5.15.1 Specialising in Solid Dosage Forms
5.16 Nipro
  5.16.1 Recent Financial Performance
  5.16.2 Outlook
5.17 Divis Laboratories
  5.17.1 Recent Financial Performance
  5.17.2 Outlook
5.18 Hospira One 2 One
5.19 Famar
  5.19.1 Expansion in Spain
5.20 Fareva
  5.20.1 Company and Facility Acquisitions 2011
5.21 Kemwell Biopharma
  5.21.1 Biologics and Biosimilars
  5.21.2 Facility Growth

6. PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY TRENDS 2012-2022: CMO PERSPECTIVE

6.1 Pharmaceutical Contract Manufacturing Market: Strengths and Weaknesses for CMOs 2011-2012
6.2 Pharmaceutical Contract Manufacturing Market: Opportunities and Threats for CMOs 2012-2022
6.3 Pharmaceutical Contract Manufacturing Market: STEP Analysis for CMOs 2012-2022
6.4 Trends in Drug Development
  6.4.1 Orphan Drug Development
  6.4.2 Biologics and Biosimilars
    6.4.2.1 Antibody-Drug Conjugates (ADCs)
    6.4.2.2 Challenges in Manufacturing Biologics
    6.4.2.3 Lyophilisation as a Service
    6.4.2.4 The Rise of Biosimilars
6.5 CMO Expansion
  6.5.1 An Increasingly Competitive Market
  6.5.2 Regional Expansion
  6.5.3 Buying Underused Facilities
    6.5.3.1 The Risk of Overcapacity
  6.5.4 CMOs as a One-Stop-Shop
  6.5.5 CMO Consolidation
  6.5.6 Manufacturing Clinical Trial Materials
  6.5.7 Pharmaceutical Companies as Competitors
6.6 Improving Manufacturing Processes
  6.6.1 Quality by Design (QbD)
  6.6.2 Batch vs. Continuous Manufacturing

7. PHARMACEUTICAL CONTRACT MANUFACTURING INDUSTRY TRENDS 2012-2022: CLIENT PERSPECTIVE

7.1 Pharmaceutical Contract Manufacturing Market: Strengths and Weaknesses for Drug Developers 2011-2012
7.2 Pharmaceutical Contract Manufacturing Market: Opportunities and Threats for Drug Developers 2012-2022
7.3 The Outsourcing Decision
  7.3.1 Reasons and Benefits to Outsourcing
  7.3.2 Risks in Outsourcing Manufacturing
  7.3.3 Selecting a CMO
  7.3.4 Globalisation vs. Localisation
  7.3.5 Using Emerging Market CMOs
  7.3.6 Strategic Partnering
7.4 Outsourcing Strategy Depends on Company Size
  7.4.1 Virtual Pharmaceutical Companies
7.5 Good Communication is Vital
  7.5.1 Technology Transfer
7.6 Regulatory Compliance
  7.6.1 The Responsibility of the Pharmaceutical Client
    7.6.1.1 Drug Recalls

8. REGULATORY ASPECTS OF PHARMACEUTICAL MANUFACTURING 2012-2022

8.1 Good Manufacturing Practice (GMP)
8.2 Global Harmonisation of Manufacturing Regulations: The ICH
  8.2.1 ICH Q11
8.3 Collaboration Between Regulatory Bodies
8.4 Pharmaceutical Manufacturing Regulation in the US
  8.4.1 Response to Industry Trends
  8.4.2 The FDA and Foreign Manufacturing Sites
  8.4.3 Generic Drug User Fee Act 2012
8.5 European Manufacturing Regulations
  8.5.1 API Regulation in the EU
    8.5.1.1 Falsified Medicine Directive
  8.5.2 Other Recent Regulation Revisions
8.6 Pharmaceutical Manufacturing in Japan
8.7 Emerging Markets and Manufacturing Regulations
  8.7.1 Brazil
  8.7.2 Russia
  8.7.3 India
  8.7.4 China
    8.7.4.1 Consequences of Stricter Regulations
8.8 South Korea

9. OPINIONS FROM OUR SURVEY: RESEARCH INTERVIEWS

9.1 Dr Franck Latrille, CEO, NextPharma Technologies
  9.1.1 NextPharma Technologies
  9.1.2 Change in Demand for Contract Manufacturing Services
  9.1.3 Opportunities for Growth and Market Restraints
  9.1.4 Growth for NextPharma
  9.1.5 The Advantages of a Full Service CMO
9.2 Mr Kevin Cook, Managing Director, API Business Unit, Aesica Pharmaceuticals
  9.2.1 Aesica Pharmaceuticals
    9.2.1.1 Recent Acquisitions
  9.2.2 Patent Expiries and the European API Manufacturing Market
  9.2.3 Opportunities for European API Manufacturers
  9.2.4 The Impact of the Falsified Medicines Directive
  9.2.5 Outlook for Aesica Pharmaceuticals

10. CONCLUSIONS

10.1 State of the Pharmaceutical Contract Manufacturing Market in 2011
10.2 Growth in the Pharmaceutical Contract Manufacturing Market 2012-2022
  10.2.1 The API Manufacturing Market 2012-2022
  10.2.2 The Finished Dosage Form Manufacturing Market 2012-2022
10.3 Regional Breakdown of the Pharmaceutical Contract Manufacturing Market 2012-2022
  10.3.1 Regional Developments in Supply of Services
  10.3.2 Regional Developments in Demand for Services
10.4 Many Opportunities Exist

LIST OF TABLES

Table 1.1 Currency Exchange Rates, 2011
Table 3.1 Pharmaceutical Contract Manufacturing Market by Sector, 2011
Table 3.2 Recent Financial Performance for the Five Leading CMOs, Combined, 2009- 2011
Table 3.3 World Biologics Market by Company, 2011
Table 3.4 Pharmaceutical Contract Manufacturing Market: Overall Market and Revenue Forecasts by Sector, 2011-2022
Table 3.5 Pharmaceutical Contract Manufacturing Submarket Shares, 2011-2022
Table 3.6 Pharmaceutical Contract Manufacturing Market: Drivers and Restraints, 2012-2022
Table 3.7 API Contract Manufacturing Submarket by Sector, 2011
Table 3.8 API Contract Manufacturing Submarket: Revenue Forecast, 2011-2022
Table 3.9 API Contract Manufacturing Market: Drivers and Restraints, 2012-2022
Table 3.10 Generic API Contract Manufacturing Submarket: Revenue Forecast, 2011-2022
Table 3.11 HPAPI Contract Manufacturing Submarket: Revenue Forecast, 2011-2022
Table 3.12 Finished Dosage Form Contract Manufacturing Submarket by Sector, 2011
Table 3.13 Finished Dosage Form Contract Manufacturing Submarket: Revenue Forecast, 2011-2022
Table 3.14 Finished Dosage Form Contract Manufacturing Market: Drivers and Restraints, 2012-2022
Table 3.15 Solid Dosage Contract Manufacturing Submarket: Revenue Forecast, 2011-2022
Table 3.16 Injectable Dosage Contract Manufacturing Submarket: Revenue Forecast, 2011-2022
Table 4.1 Pharmaceutical Contract Manufacturing Market by Country, 2011
Table 4.2 Pharmaceutical Contract Manufacturing Market: Revenue Forecasts by Country, 2011-2022
Table 4.3 Pharmaceutical Contract Manufacturing: Market Shares by Country, 2011-2022
Table 4.4 US Submarket: Revenue Forecast, 2011-2022
Table 4.5 Pharmaceutical Contract Manufacturing: EU Market by Country, 2011
Table 4.6 EU Pharmaceutical Contract Manufacturing Market: Revenue Forecasts by Leading Country 2011-2022
Table 4.7 German Submarket: Revenue Forecast, 2011-2022
Table 4.8 French Submarket: Revenue Forecast, 2011-2022
Table 4.9 Italian Submarket: Revenue Forecast, 2011-2022
Table 4.10 Spanish Submarket: Revenue Forecast, 2011-2022
Table 4.11 UK Submarket: Revenue Forecast, 2011-2022
Table 4.12 Japanese Submarket: Revenue Forecast, 2011-2022
Table 4.13 Brazilian Submarket: Revenue Forecast, 2011-2022
Table 4.14 Russian Submarket: Revenue Forecast, 2011-2022
Table 4.15 Indian Submarket: Revenue Forecast, 2011-2022
Table 4.16 Chinese Submarket: Revenue Forecast, 2011-2022
Table 4.17 South Korean Submarket: Revenue Forecast, 2011-2022
Table 5.1 Pharmaceutical Contract Manufacturing Market by Company, 2011
Table 5.2 Selected Manufacturing Deals for Leading CMOs, 2011-2012
Table 5.3 Capacity Expansion for Leading CMOs, 2011-2012
Table 5.4 Catalent: Revenue by Division, 2009-2011
Table 5.5 Lonza: Custom Manufacturing Revenue, 2009-2011
Table 5.6 Boehringer Ingelheim: Contract Manufacturing Revenue by Division, 2009-2011
Table 5.7 DSM: Contract Manufacturing Revenue, 2009-2011
Table 5.8 DSM: Contract Manufacturing Revenue by Division, 2010-2011
Table 5.9 Patheon: Contract Manufacturing Revenue by Division, 2009-2011
Table 5.10 Global DMFs Submitted by Dr. Reddy's Laboratories to 2012
Table 5.11 Dr. Reddy's Laboratories: Contract Manufacturing Revenue, 2010-2012
Table 5.12 Jubilant Life Sciences: Contract Manufacturing Revenue by Division, 2009-2011
Table 5.13 Haupt Pharma: Revenue, 2005-2011
Table 5.14 Recipharm: Revenue by Customer Type, 2011
Table 5.15 Recipharm: Revenue by Region, 2009-2011
Table 5.16 Pfizer: Contract Manufacturing Revenue by Region, 2009-2011
Table 5.17 Piramal Pharma Solutions: Contract Manufacturing Revenue by Region, 2011-2012
Table 5.18 Nipro: Pharmaceutical Business Revenue, 2010-2012
Table 5.19 Divis Laboratories: Contract Manufacturing Revenue by Region, 2011-2012
Table 6.1 Pharmaceutical Contract Manufacturing Market Strengths and Weaknesses: CMO Perspective, 2012
Table 6.2 Pharmaceutical Contract Manufacturing Market Opportunities and Threats: CMO Perspective, 2012-2022
Table 6.3 Pharmaceutical Contract Manufacturing Market: STEP Analysis, 2012-2022
Table 6.4 Selected Pharmaceutical Industry Facility Buyouts, 2011-2012
Table 7.1 Pharmaceutical Contract Manufacturing Market Strengths and Weaknesses: Client Perspective, 2012
Table 7.2 Pharmaceutical Contract Manufacturing Market Opportunities and Threats: Client Perspective, 2012-2022
Table 7.3 Comparison of Selected European and Indian API Manufacturers
Table 8.1 ICH Guidelines: Key Facts and Adoption, 2000-2012
Table 9.1 NextPharma Technologies: Global Locations and Capabilities, 2012
Table 10.1 Pharmaceutical Contract Manufacturing Market: Revenues by Sector, 2011, 2016 and 2022
Table 10.2 Pharmaceutical Contract Manufacturing Market: Revenues by Region, 2011, 2016 and 2022

LIST OF FIGURES

Figure 2.1 Selected Tasks Outsourced in the Pharmaceutical Industry, 2012
Figure 2.2 The Rise of Contract Development and Manufacturing Organisations
Figure 3.1 Pharmaceutical Contract Manufacturing Market by Sector, 2011
Figure 3.2 Recent Financial Performance for the Five Leading CMOs, Combined, 2009-2011
Figure 3.3 World Biologics Market by Company, 2011
Figure 3.4 Pharmaceutical Contract Manufacturing Market: Overall Market Forecast, 2011-2022
Figure 3.5 Pharmaceutical Contract Manufacturing: Market Shares by Sector, 2016
Figure 3.6 Pharmaceutical Contract Manufacturing: Market Shares by Sector, 2022
Figure 3.7 API Contract Manufacturing Submarket by Sector, 2011
Figure 3.8 API Contract Manufacturing Submarket: Revenue Forecast, 2011-2022
Figure 3.9 Generic API Contract Manufacturing: Submarket Revenue Forecast, 2011-2022
Figure 3.10 HPAPI Contract Manufacturing Submarket: Revenue Forecast, 2011-2022
Figure 3.11 Finished Dosage Form Contract Manufacturing Submarket by Sector, 2011
Figure 3.12 Finished Dosage Form Contract Manufacturing Submarket: Revenue Forecast, 2011-2022
Figure 3.13 Solid Dosage Contract Manufacturing Submarket: Revenue Forecast, 2011-2022
Figure 3.14 Injectable Dosage Contract Manufacturing Submarket: Revenue Forecast, 2011-2022
Figure 4.1 Pharmaceutical Contract Manufacturing: Market Shares by Country, 2011
Figure 4.2 Pharmaceutical Contract Manufacturing: Market Shares by Country, 2016
Figure 4.3 Pharmaceutical Contract Manufacturing: Market Shares by Country, 2022
Figure 4.4 US Submarket: Revenue Forecast, 2011-2022
Figure 4.5 Pharmaceutical Contract Manufacturing: EU Market by Country, 2011
Figure 4.6 EU Submarket: Revenue Forecast, 2011-2022
Figure 4.7 German Submarket: Revenue Forecast, 2011-2022
Figure 4.8 French Submarket: Revenue Forecast, 2011-2022
Figure 4.9 Italian Submarket: Revenue Forecast, 2011-2022
Figure 4.10 Spanish Submarket: Revenue Forecast, 2011-2022
Figure 4.11 UK Submarket: Revenue Forecast, 2011-2022
Figure 4.12 Japanese Submarket: Revenue Forecast, 2011-2022
Figure 4.13 Brazilian Submarket: Revenue Forecast, 2011-2022
Figure 4.14 Russian Submarket: Revenue Forecast, 2011-2022
Figure 4.15 Indian Submarket: Revenue Forecast, 2011-2022
Figure 4.16 Chinese Submarket: Revenue Forecast, 2011-2022
Figure 4.17 South Korean Submarket: Revenue Forecast, 2011-2022
Figure 5.1 Pharmaceutical Contract Manufacturing Market by Company, 2011
Figure 5.2 Catalent: Revenue by Division, 2011
Figure 5.3 Lonza: Custom Manufacturing Revenue, 2009-2011
Figure 5.4 Boehringer Ingelheim: Contract Manufacturing Revenue by Division, 2009-2011
Figure 5.5 DSM: Contract Manufacturing Revenue, 2009-2011
Figure 5.6 Patheon: Contract Manufacturing Revenue by Division, 2009-2011
Figure 5.7 Dr. Reddy's Laboratories: Contract Manufacturing Revenue, 2010-2012
Figure 5.8 Jubilant Life Sciences: Contract Manufacturing Revenue by Division, 2009-2011
Figure 5.9 Haupt Pharma: Revenue, 2005-2011
Figure 5.10 Recipharm: Revenue by Customer Type, 2011
Figure 5.11 Recipharm: Revenue by Region, 2009-2011
Figure 5.12 Pfizer: Contract Manufacturing Revenue by Region, 2009-2011
Figure 5.13 Piramal Pharma Solutions: Contract Manufacturing Revenue by Region, 2011-2012
Figure 5.14 Nipro: Pharmaceutical Business Revenue, 2010-2012
Figure 5.15 Divis Laboratories: Contract Manufacturing Revenue by Region, 2011-2012
Figure 6.1 World Biological Drugs Market Forecast, 2011, 2016 and 2022
Figure 6.2 World Lyophilisation Services and Products: Market Forecasts, 2011, 2016 and 2022
Figure 8.1 Overview of ICH Manufacturing Guidelines, 2012
Figure 9.1 Aesica Pharmaceuticals: Revenue 2010-2011
Figure 10.1 Pharmaceutical Contract Manufacturing Market: Revenues by Sector, 2011, 2016 and 2022
Figure 10.2 Pharmaceutical Contract Manufacturing Market: Revenues by Region, 2011, 2016 and 2022

COMPANIES LISTED

Abbott Contract Manufacturing (part of Abbott Laboratories)
Abbott Laboratories
ADVENTRX Pharmaceuticals
Aenova (formerly Dragenopharm Apotheker Pьschl and Swiss Caps)
Aesica Pharmaceuticals
Agкncia Nacional de Vigilвncia Sanitбria (ANVISA) [Brazil]
Agennix
Albany Molecular Research (AMRI)
Alexion Pharmaceuticals
Amgen
Aptuit
Athera Biotechnologies
Avalanche Biotechnologies
AVEO Pharmaceuticals
Avesthagen
BASF
Ben Venue Laboratories (part of Boehringer Ingelheim)
Bend Research
Biogen Idec
Blackstone Group
Boehringer Ingelheim
Bristol-Myers Squibb
Cambridge Major Laboratories (CML)
Cardinal Health
Catalent
Celltrion
Centocor (now known as Janssen Biologics)
CMIC CMO
Cobra Biologics Holding
Daiichi Sankyo
Department of Pharmaceuticals [India]
Divis Laboratories
Dr. Reddy's Laboratories
DSM Sinochem Pharmaceuticals (DSP)
Eclipse Therapeutics
Elan
Eli Lilly
Emcure Pharmaceuticals
Enobia Pharma (part of Alexion Pharmaceuticals)
European Commission (EC)
European Medicines Agency (EMA)
Evonik Degussa (part of Evonik Industries)
Evonik Industries
Famar
Fareva
Farmhispania
FDA Office of Combination Products (OCP) [US]
Food and Drug Administration (FDA) [US]
Frazier Healthcare
Gallus BioPharmaceuticals
GEA Lyophil
Government Accountability Office (GAO) [US]
GSK
Halo Pharmaceuticals
Haupt Pharma
Hikal
Hospira
Hospira One 2 One (part of Hospira)
Human Genome Sciences (part of GSK)
Immune Pharmaceuticals
Infa Group
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
Jubilant HollisterStier (part of Jubilant Life Sciences)
Jubilant Life Sciences
Kemwell Biopharma
Kensey Nash
Korea Food and Drug Administration (KFDA)
Lonza
Marinopoulos Group
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Mesoblast
Ministry of Health, Labor and Welfare (MHLW) [Japan]
MorphoSys
Nascent Biologics
NextPharma Technologies
Nipro
NKT Therapeutics
Novartis
Nycomed (part of Takeda Pharmaceutical)
Pantec
Patheon
Pfizer
Pfizer CentreSource (part of Pfizer)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
Piramal Healthcare
ProBioGen
Procaps
QRxPharma
Quintiles
R5 (part of Aesica Pharmaceuticals)
Recepta Biopharma
Recipharm
RecipharmCobra Biologics (part of Cobra Biologics Holding)
Roche
Royal DSM
SafeBridge Consultants
Samsung
Samsung BioLogics
Sanofi
SCM Pharma
Seattle Genetics
Sigmar Italia (part of Fareva)
Silverfleet Capital
Sinochem
SkyePharma
State Food and Drug Administration (SFDA) [China]
Sun Capital Partners
SurModics (part of Evonik Industries)
Swedbank
Teva Pharmaceutical Industries
Therapeutic Goods Administration (TGA) [Australia]
UCB
Uquifa
Vetter Pharma-Fertigung
Vivante GMP Solutions (part of Lonza)
Wasserburger Arzneimittelwerk (part of Recipharm)
Wockhardt
World Health Organization (WHO)
Xencor
Skip to top


Ask Your Question

Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: